MENU
BBH
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

BBH stock forecast, quote, news & analysis

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® U... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
BBH
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for BBH with price predictions
Oct 23, 2026

BBH's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for BBH turned positive on October 20, 2026. Looking at past instances where BBH's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on BBH as a result. In 77 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBH advanced for three days, in 248 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 209 of 255 cases where BBH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

BBH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® U.S. Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Biotech ETF (BBH) ETF is 46.17B. The market cap for tickers in the group ranges from 10.41B to 237.48B. AMGN holds the highest valuation in this group at 237.48B. The lowest valued company is QGEN at 10.41B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Biotech ETF (BBH) ETF was 2%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was 33%. CRL experienced the highest price growth at 15%, while MRNA experienced the biggest fall at -8%.

Volume

The average weekly volume growth across all stocks in the VanEck Biotech ETF (BBH) ETF was -13%. For the same stocks of the ETF, the average monthly volume growth was 3% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 57
Price Growth Rating: 37
SMR Rating: 67
Profit Risk Rating: 71
Seasonality Score: 27 (-100 ... +100)